desipramine has been researched along with Movement Disorders in 6 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dupre, KB | 1 |
| Eskow, KL | 1 |
| Barnum, CJ | 1 |
| Bishop, C | 1 |
| Takahashi, T | 1 |
| Kobayashi, T | 1 |
| Ozaki, M | 1 |
| Takamatsu, Y | 1 |
| Ogai, Y | 1 |
| Ohta, M | 1 |
| Yamamoto, H | 1 |
| Ikeda, K | 1 |
| Mintz, M | 1 |
| Douglas, RJ | 1 |
| Tomer, R | 1 |
| de Villiers, AS | 1 |
| Kellaway, L | 1 |
| Markham, CH | 1 |
| Kaufmann, W | 1 |
| Butz, P | 1 |
| Wiesendanger, M | 1 |
| Tissot, R | 1 |
| Gaillard, JM | 1 |
| Guggisberg, M | 1 |
| Gauthier, G | 1 |
| de Ajuriaguerra, J | 1 |
6 other studies available for desipramine and Movement Disorders
| Article | Year |
|---|---|
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine | 2008 |
G protein-activated inwardly rectifying K+ channel inhibition and rescue of weaver mouse motor functions by antidepressants.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2006 |
Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.
Topics: Amphetamine; Animals; Corpus Striatum; Desipramine; Dominance, Cerebral; Drug Tolerance; Hydroxydopa | 1986 |
The "on-off" side effect of L-DOPA.
Topics: Age Factors; Amitriptyline; Aromatic Amino Acid Decarboxylase Inhibitors; Athetosis; Carbidopa; Cate | 1974 |
[Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
Topics: Aged; Carboxy-Lyases; Desipramine; Dihydroxyphenylalanine; Discrimination, Psychological; Drug Syner | 1969 |
[Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
Topics: Adult; Aged; Anemia, Hemolytic; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Cell Count; Carb | 1969 |